Evidence map›Paper›PMID 37848970›Full record

Trial reportAddiction science & clinical practice2023

Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.

Shannon Gwin Mitchell, Julia Jester, Jan Gryczynski, Melanie Whitter, Douglas Fuller, Caroline Halsted, Robert P Schwartz

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04188977 (Facilitating the Implementation of Interim Methadone to Increase Treatment Access), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04188977 nacompletednot on this map

Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial

TypeinterventionalSponsorFriends Research Institute, Inc.Ran2019 to 2022Enrolled18ConditionsOpioid-use DisorderArmsUsual Practice, Implementation Facilitation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shannon Gwin MitchellFriends Research Institute, Inc., 1040 Park Avenue, Baltimore, MD, 21201, USA. smitchell@friendsresearch.org.ORCID http://orcid.org/0000-0002-2841-1085
Julia JesterMid Shore Pro Bono, Easton, MD, USA.
Jan GryczynskiFriends Research Institute, Inc., 1040 Park Avenue, Baltimore, MD, 21201, USA.
Melanie WhitterNational Association of State Alcohol and Drug Abuse Directors, Inc., Washington, D.C., USA.
Douglas FullerNational Association of State Alcohol and Drug Abuse Directors, Inc., Washington, D.C., USA.
Caroline HalstedNational Association of State Alcohol and Drug Abuse Directors, Inc., Washington, D.C., USA.
Robert P SchwartzFriends Research Institute, Inc., 1040 Park Avenue, Baltimore, MD, 21201, USA.
Friends Research Institute · USNational Association of State Alcohol and Drug Abuse Directors · US

Funding

Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation TrialU01DA046910 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI SCHWARTZ, ROBERT P · 2018 to 2021
$4.8M
NIDA NIH HHS U01 DA046910
6 · The paper itself

Abstract

backgroundDuring the COVID-19 pandemic, federal regulations in the USA for methadone treatment of opioid use disorder (OUD) were temporarily revised to reduce clinic crowding and promote access to treatment.

methodsAs part of a study seeking to implement interim methadone without routine counseling to hasten treatment access in Opioid Treatment Programs with admission delays, semi-structured qualitative interviews were conducted via Zoom with participating staff (N = 11) in six OTPs and their State Opioid Treatment Authorities (SOTAs; N = 5) responsible for overseeing the OTPs' federal regulatory compliance. Participants discussed their views on the response of OTPs in their states to the pandemic and the impact of the COVID-related regulatory flexibilities on staff, established patients, and new program applicants. Interviews were audio recorded, transcribed, and a content analysis was conducted using ATLAS.ti.

resultsAll SOTAs requested the blanket take-home exemption and supported the use of telehealth for counseling. Participants noted that these changes were more beneficial for established patients than program applicants. Established patients were able to obtain a greater number of take-homes and attend individual counseling remotely. Patients with limited resources had greater difficulty or were unable to access remote counseling. The convenience of intake through telehealth did not extend to new program applicants because the admission physical exam requirement was not waived.

conclusionsThe experienced reflections of SOTAs and OTP providers on methadone practice changes during the COVID-19 pandemic offer insights on SAMHSA's proposed revisions to its OTP regulations. Trial registration Clinicaltrials.gov # NCT04188977.

Indexed as

COVID-19Opioid-Related DisordersAnalgesics, OpioidHumansMethadoneOpiate Substitution TreatmentPandemicsAnalgesics, OpioidMethadoneCOVIDMethadone treatmentOpioid treatment programsOpioid use disorder treatmentRegulations

Identifiers

PMID37848970
PMCPMC10580566
OpenAlexW4387703137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.